Sixth Alpine Meeting – Enhancing the Efficacy of cancer Drugs – the Need for a Paradigma Shift

4th-6th October 2011
Innsbruck, Austria

Tuesday 4 October 2011

Plenary Session 1 14:30 - 16:40

Welcome and Introduction H. Zwierzina

Review of Current Challenges of Drug Development
Co-Chairs: B. Jonsson, W. Wein, H. Zwierzina

Drug Development Strategies: How to Raise the Bar. Speaker: H. Zwierzina, BDA
Biomarkers - Working Towards a Common Understanding. Speaker: W. Wein, Merck-Serono
State of the Art - What has Been Achieved Clinically?
Signal Transduction Inhibitors: Single Versus Multi-Targeted Drugs. Speaker: F. Puehler, Bayer-Schering
Signal Transduction Inhibitors: Overcoming Primary and Secondary Resistance Mechanisms. Speaker: Y. Yarden, Rehovot
Resistance Mechanisms in Anti-Angiogenesis Treatment. Speaker: M. Belting, Lund

Open Forum Discussion

Plenary Session 2 17:00 - 19:00

Future Strategies - Identification of Relevant Mechanisms of Action
Co-Chairs: L. Håkansson, G. Schlueter

Challenges of Bioinformatics in Cancer drug development. Speaker: Z. Trajanoski, Innsbruck
What Can We Learn From Neo-Adjuvant Studies? Speaker: J. Larkin, London
Selection of Therapeutic Targets: A Regulatory Perspective. Speaker: B. Jonsson, MPA

Open Forum Discussion

Welcome Reception and Networking Dinner 19:30

Wednesday 5 October 2011

Plenary Session 3 08:30 - 12:30

Personalised Medicine in Cancer Care: Is Progress Being Made?
Part One
Co-Chairs: E. Skovlund, J. Smyth, P. Zapella

The International Cancer Genome Consortium - Progress and Challenges. Speaker: P. Lichter, Heidelberg

Molecular Sceening of Tumours: A Future Standard Diagnostic Procedure for Personalised Therapy. Speaker: R. Mader, Vienna
Challenges of Innovative Trial Designs - A Regulator's Perspective. Speaker: E. Skovlund, NoMa
When Personalised Medicine in Cancer Care is Adopted Who Are The Main Beneficiaries?
Industry Perspective. Speaker: N. Bederski, Merck-Serono
Academic Perspective. Speaker: J. Smyth, Edinburgh
Payer Perspective. Speaker: F. Bittner, Vienna

Open Forum Discussion

Part Two
Co-Chairs: J. DiMartino, A. Shimosaka

How to Run Orphan Drug Trials in Patient Populations of Different Ethnicity. Speaker: A. Shimosaka, ISCT
Drug-Diagnostic Co- Development: Opportunities, Challenges and Pitfalls. Speaker: K. Hood, Roche

Open Forum Discussion

Lunch

Plenary Session 4 13:30 - 14:30

Upcoming Strategies for Biomarker Research
Co-Chairs: K. Hood, Z. Trajanoski

Circulating Cancer Cells and Cancer Stem Cells. Speaker: S. Kasimir-Bauer, Essen
Multivariate Testing Using MALDI ToF Mass Spectrometry. Speaker: H. Roder, Biodesix

Breakout Sessions 14:30 - 16:00

1. Benefit-Risk Assessment – Methodology for Oncology Drugs. Co-Chairs: J. Smyth, S. Schwoch, C. Baumgartl
2. Drug-Diagnostic Co-Development. Co-Chairs: H. Niefenthaler, M. Scheulen, E. Skovlund

Coffee Break

Plenary Session 5 16:30 - 18:00
Co-Chairs: N. Botwood, M. Scheulen

Report from Breakout Sessions

Pre-Clinical Biomarker Development. Speaker: J. DiMartino, Celgene
Clinical Experiences with Combination New Molecular Entities. Speaker: M. Scheulen, Essen

Open Forum Discussion

BDA Meeting with Industry Panel 18:30 – 19.30

Networking Dinner 19:45

Thursday 6 October 2011

Breakout Sessions 08:30 - 10:00

3. Endpoints for Early Stage Diseases - Why do PFS and OS Frequently Differ? Co-Chairs: TBCs
4. Immunotherapy - Achievements and Future Developments Co-Chairs: L. Håkansson, Malmö, M. Schüssler-Lenz, Paul Ehrlich Institut

Coffee Break

Report from Breakout Sessions 10:30

Plenary Session 6 10:45 - 12:15
Co-Chairs: S. Schwoch, H. Zwierzina

Regulatory Requirements for Starting Early Clinical Trials. Speaker: TBC
EMA NfG Anti-Cancer Guideline: Status and Next Steps. Speaker: B. Jonsson, MPA

End of Meeting